Acumen Pharmaceuticals, Inc.
ABOS
$2.97
-$0.20-6.17%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 20.10% | 27.99% | 32.34% | 11.13% | -99.40% |
| Total Depreciation and Amortization | -4.26% | 2.22% | 2.27% | 4.44% | 4.44% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.29% | 15.51% | 79.39% | 111.58% | 1,436.26% |
| Change in Net Operating Assets | 87.06% | 22.06% | -63.58% | -288.16% | 66.67% |
| Cash from Operations | 43.22% | 29.29% | 29.83% | -23.96% | -92.40% |
| Capital Expenditure | -- | -- | -- | -- | -80.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -32.45% | -147.99% | -11.51% | 499.83% | 2.09% |
| Cash from Investing | -32.44% | -148.13% | -11.51% | 499.83% | 2.08% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 96,902.70% | -- | -- | -- |
| Repurchase of Common Stock | -- | -104.11% | 100.00% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | 99,383.33% | 122.22% | 100.00% | 100.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 14.98% | 59.89% | 193.40% | 128.82% | -68.37% |